https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
68; 95% confidence interval [CI], 2.82-4.81; P.0001) as well as in both cohorts separately (bioprosthetic HR, 4.35; 95% CI, 3.05-6.22; P.001; mechanical HR, 2.54; 95% CI, 1.59-4.03; P.001). Patients with an in-hospital NOAF also had a significantly higher adjusted risk of death during the follow-up in the mechanical (HR, 2.05; 95% CI, 1.10-3.82; P=.025) and bioprosthetic (HR, 1.63; 95% CI, 1.17-2.28; P=.004) valve prosthesis cohorts. NOAF during the index hospitalization is associated with a 2- to 4-fold risk of
Like
Comment
Share
